Using transcutaneous oxygen pressure measurements as selection criteria for activated protein C use

Journal of Trauma - Injury, Infection and Critical Care

Volumn 65, Issue 1, 2008, Pages 30-33

  Chapital, Alyssa D ^a,b,c   Yu, Mihae ^a,b   Ho, Hao Chih ^a,b   Wang, John ^a   Koss, Wega ^a,b   Takanishi, Danny M ^a,b  

^a UNIVERSITY OF HAWAII   (United States)

^b Department of Pediatrics   (United Kingdom)

^c Department of Critical Care Medicine   (United States)

Author keywords

Activated protein C; Drotrecogin alfa; Perfusion; Sepsis; Shock; Transcutaneous oxygen

Indexed keywords

ADRENALIN; DIURETIC AGENT; DOBUTAMINE; DROTRECOGIN; LACTIC ACID; MILRINONE; NORADRENALIN; OXYGEN; ANTIINFECTIVE AGENT; PROTEIN C; RECOMBINANT PROTEIN;

ADULT; AGE DISTRIBUTION; AGED; APACHE; ARTICLE; CLINICAL ARTICLE; DEATH; DRUG DOSE TITRATION; DRUG USE; FEMALE; HUMAN; HYPERVOLEMIA; ISCHEMIA; MALE; MICROCIRCULATION; MORTALITY; MULTIPLE ORGAN FAILURE; PRIORITY JOURNAL; SEPSIS; SEPTIC SHOCK; SEX RATIO; SURVIVAL; SURVIVOR; TISSUE PERFUSION; TRANSCUTANEOUS OXYGEN MONITORING; BLOOD; CLINICAL TRIAL; HEALTH SURVEY; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SELECTION; REPRODUCIBILITY; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-INFECTIVE AGENTS; BLOOD GAS MONITORING, TRANSCUTANEOUS; FEMALE; HEALTH STATUS INDICATORS; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; PATIENT SELECTION; PROTEIN C; RECOMBINANT PROTEINS; REPRODUCIBILITY OF RESULTS; SEPSIS; TREATMENT OUTCOME;

EID: 67649921586     PISSN: 00225282     EISSN: 15298809     Source Type: Journal    
DOI: 10.1097/TA.0b013e3180eeab28     Document Type: Article

References (35)

1. Bernard G, Vincent J, Laterre PF, et al. Efficacy and safety of recombinant human Activated Protein C for severe sepsis. N Engl J Med. 2001;344:699-709.
2. De Backer D, Verdant C, Chierego M, Koch M, Gullo A, Vincent JL. Effects of drotrecogin alfa activated on microcirculatory alterations in patients with severe sepsis. Crit Care Med. 2006; 34:1918-1924.
3. Yu M, Morita SY, Daniel SR, Chapital A, Waxman K, Severino R. Transcutaneous pressure of oxygen: a non-invasive and early detector of peripheral shock and outcome. Shock. 2006;26:450-456.
4. Matsen FA III, Wyss CR, King RV, Simmons CW. Effect of acute hemorrhage on transcutaneous, subcutaneous, intramuscular and arterial oxygen tensions. Pediatrics. 1980;65:881-883.
5. Tremper K, Waxman K, Bowman R, Shoemaker WC. Continuous transcutaneous oxygen monitoring during respiratory failure, cardiac decompensation, cardiac arrest and CPR. Crit Care Med. 1980; 8:377-381.
6. Mckinley BA, Parmley CL, Butler BD. Skeletal muscle pO2, pCO2, and pH in hemorrhage, shock and resuscitation in dogs. J Trauma. 1998;44:119-127.
7. Tremper K, Shoemaker W. Transcutaneous oxygen monitoring of critically ill adults, with and without low flow shock. Crit Care Med. 1981;9:706-709.
8. Tremper KK, Shoemaker WC, Shippy CR, Nolan LS. Transcutaneous PCO2 monitoring on adult patients in the ICU and the operating room. Crit Care Med. 1981;9:752-755.
9. Waxman K, Sadler R, Eisner M, Applebaum R, Tremper KK, Mason GR. Transcutaneous oxygen monitoring of emergency department patients. Am J Surg. 1983;146:35-38.
10. Tremper KK, Barker SJ. Transcutaneous oxygen measurement: experimental studies and adult applications. Int Anesthesiol Clin. 1987;25:67-97.
11. Abraham E, Smith M, Silver L. Continuous monitoring of critically ill patients with transcutaneous oxygen and carbon dioxide and conjunctiva oxygen sensors. Ann Emerg Med. 1984;13:1021-1026.
12. Reed RL II, Maier RV, Lanicho D, Kenny MA, Carrico CJ. Correlation of hemodynamic variables with transcutaneous PO2 measurements in critically ill adult patients. J Trauma. 1985; 25:1045-1051.
13. Green GE, Hassell KT, Mahutte K. Comparison of arterial blood gas with continuous intra-arterial and transcutaneous PO2 sensors in adult critically ill patients. Crit Care Med. 1987;15:491-494.
14. Jonsson K, Jensen JA, Goodson WH, West JM, Hunt TK. Assessment of perfusion in postoperative patients using tissue oxygen measurements. Br J Surg. 1987;74:263-267.
15. Esbroeck GV, Gys T, Hubens A. Evaluation of tissue oximetry in perioperative monitoring of colorectal surgery. Br J Surg. 1992; 79:584-587.
16. Waxman K, Annas C, Daughters K, Tominaga GT, Scannell G. A method to determine the adequacy of resuscitation using tissue oxygen monitoring. J Trauma. 1994;36:852-856; discussion 856-858.
17. Xigris [package insert]. Indianapolis, IN: Eli Lilly and Company; 2003.
18. Siegel J. Assessing the use of activated protein C in the treatment of severe sepsis. N Eng J Med. 2002;347:1030-1034.
19. Glance L, Osler T, Papadakos P. Effect of mortality rate on the performance of the acute physiology and chronic health evaluation II: a simulation study. Crit Care Med. 2000;28:3424-3428.
20. Barie PS, McCollam JS, Williams MD, et al. Drotrecogin alfa (activated) has a favorable benefit/risk profile in surgical patients with severe sepsis. Crit Care Med. 2002;30(suppl 12):A102.
21. Warren S, Suffredini A, Eichacker P, et al. Risks and Benefits of Activated Protein C Treatment for severe sepsis. N Engl J Med. 2002;347:1027-1030.
22. Vassar M, Levis F, Chambers J, et al. Prediction of outcome in intensive care unit trauma patients: a multicenter study of acute physiology and chronic health evaluation (APACHE), trauma and injury severity score (TRISS) and 24-hour intensive care (ICU) point system. J Trauma. 1999;47:324-329.
23. Beck DH, Taylor BL, Millar B, Smith GB. Prediction of outcome from an intensive care: a prospective cohort study comparing acute physiology and chronic health evaluation II and III prognostic systems in a United Kingdom intensive care unit. Crit Care Med. 1997;25:9-15.
24. Wheeler A, Doig C, Wright T, et al. Baseline characteristics and survival of adult severe sepsis patients treated with Drotrecogin Alfa (activated) in a global, single-arm, open-labeled trail (ENHANCE). Chest. 2003;124:91S-92S.
25. Huch R, Huch A, Lubbers D. Transcutaneous measurement of blood PO2 (tcPO2)-Method and application in perinatal medicine. J Perinat Med. 1973;1:183-191.
26. Goeckenjan G, Strasser K. Relation of transcutaneous to arterial PO2 in hypoxaemia, normoxaemia and hyperoxaemia. Biotelemetry. 1977; 4:77-87.
27. Tremper K, Waxman K, Shoemaker W. Effects of hypoxia and shock on transcutaneous PO2 value in dogs. Crit Care Med. 1979; 7:526-531.
28. Shoemaker W, Vidyasagar D. Physiological and clinical significance of PtcO2 and PtcCO2 measurements. Crit Care Med. 1981;9:689-690.
29. Wagener J, Hendricker C. Intrasubject variability of noninvasive oxygen measurements. Chest. 1987;92:1047-1049.
30. Takiwaki H, Nakanishi H, Shono Y, Arase S. The influence of cutaneous factors on the transcutaneous pO2 and pCO2 at various body sites. Br J Dermatol. 1991;125:243-247.
31. Mars M, Mill RP, Robbs JV. The potential benefit of pre-op assessment of amputation wound healing potential in peripheral vascular disease. S Afr Med J. 1993;83:16-18.
32. Bongard O, Krahenbuhl B. Predicting amputation in sever ischaemia. The value of transcutaneous PO2 measurement. J Bone Joint Surg. 1988;70:465-467.
33. Furnas H, Rosen JM. Monitoring in microvascular surgery. Ann Plast Surg. 1991;26:265-272.
34. Tatevossian R, Wo C, Velmahos G, Demetriades D, Shoemaker WC. Transcutaneous oxygen and CO2 as early warning of tissue hypoxia and hemodynamic shock in critically ill emergency patients. Crit Care Med. 2000;28:2248-2252.
35. Shoemaker W, Wo C, Chan L, et al. Outcome prediction of emergency patients by noninvasive hemodynamic monitoring. Chest. 2001;120:528-537.